Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility
J Cyst Fibros
.
2024 Mar;23(2):368-369.
doi: 10.1016/j.jcf.2024.02.014.
Epub 2024 Mar 4.
Authors
Jaime L Rubin
1
,
James L Kreindler
2
Affiliations
1
Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: jaime_rubin@vrtx.com.
2
Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: james_kreindler@vrtx.com.
PMID:
38438296
DOI:
10.1016/j.jcf.2024.02.014
No abstract available
Publication types
Letter
MeSH terms
Chloride Channel Agonists / therapeutic use
Cystic Fibrosis Transmembrane Conductance Regulator* / genetics
Cystic Fibrosis* / drug therapy
Humans